ATAI - ATA Inc-China Stock Price, Fair Value and News

1.60USD+0.02 (+1.27%)Market Closed

Market Summary

USD1.60+0.02

Market Closed

1.27%

ATAI Stock Price

View Fullscreen

ATAI RSI Chart

ATAI Valuation

Market Cap

267.8M

Price/Earnings (Trailing)

-3.05

Price/Sales (Trailing)

853.02

EV/EBITDA

-9.19

Price/Free Cashflow

-3.13

ATAI Price/Sales (Trailing)

ATAI Profitability

EBT Margin

-10131.05%

Return on Equity

-39.42%

Return on Assets

-32.6%

Free Cashflow Yield

-31.94%

ATAI Fundamentals

ATAI Revenue

Revenue (TTM)

314.0K

Rev. Growth (Yr)

-52.63%

Rev. Growth (Qtr)

-79.31%

ATAI Earnings

Earnings (TTM)

-87.7M

Earnings Growth (Yr)

19.38%

Earnings Growth (Qtr)

63.01%

Breaking Down ATAI Revenue

Last 7 days

8.1%

Last 30 days

23.1%

Last 90 days

-17.1%

Trailing 12 Months

-21.6%

How does ATAI drawdown profile look like?

ATAI Financial Health

Current Ratio

7.83

Debt/Equity

0.07

Debt/Cashflow

-5.65

ATAI Investor Care

Shares Dilution (1Y)

0.84%

Diluted EPS (TTM)

-0.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	252.0K	271.0K	334.0K	314.0K
2022	0	13.7M	6.9M	233.0K
2021	0	0	0	20.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About ATA Inc-China

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

CEO	Mr. Florian Brand
WEBSITE	atai.life
INDUSTRY	Biotechnology
EMPLOYEES	133

ATA Inc-China Frequently Asked Questions

What is the ticker symbol for ATA Inc-China? What does ATAI stand for in stocks?

ATAI is the stock ticker symbol of ATA Inc-China. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ATA Inc-China (ATAI)?

As of Fri Jul 26 2024, market cap of ATA Inc-China is 267.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATAI stock?

You can check ATAI's fair value in chart for subscribers.

Is ATA Inc-China a good stock to buy?

The fair value guage provides a quick view whether ATAI is over valued or under valued. Whether ATA Inc-China is cheap or expensive depends on the assumptions which impact ATA Inc-China's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATAI.

What is ATA Inc-China's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, ATAI's PE ratio (Price to Earnings) is -3.05 and Price to Sales (PS) ratio is 853.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATAI PE ratio will change depending on the future growth rate expectations of investors.